Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions

Ronald Crystal, Ben Gary Harvey, Juan P. Wisnivesky, Kelley A. O’Donoghue, Karen W. Chu, Jaman Maroni, Jolene C. Muscat, Allison L. Pippo, Connie E. Wright, Robert J. Kaner, Philip L. Leopold, Paul D. Kessler, Henrik S. Rasmussen, Todd K. Rosengart, Charleen Hollmann

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

In this study we analyze the adverse events and abnormal laboratory parameters following local administration of low (<109particle units) and intermediate (109-1011particle units) single and repetitive doses (140 total) of E1E3adenovirus (Ad) gene transfer vectors administered to the respiratory epithelium, solid tumors, skin, myocardium, and skeletal muscle in eight gene transfer trials since April 1993. In the accompanying paper by Harvey et al., (Hum. Gene Ther. 2002; 13:15-63), we conclude that for the total group, no deaths were attributable to the Ad vectors per se, and the incidence of major adverse events likely caused by an Ad vector was 0.7%. The present study analyzes the trials as a group to evaluate risk factors for the adverse events, abnormal values among laboratory parameters, and known deaths. Ten putative risk factors were assessed, including "patient-related" (age, sex, comorbid index and pretherapy anti-Ad antibodies), "vector-related" (dose, route, transgene, and number of vector administrations), and "trial-related" (trial in which the individual was enrolled, and whether surgery was part of the trial). While assessment of each factor individually suggested several possible associations with adverse events, abnormal laboratory parameters, or deaths, multivariate analysis identified only age, comorbid index, and surgery (comorbid index for death; age and surgery for nondeath adverse events) as variables significantly associated with increased risk for a major (severity scale 3-4 of 4) adverse event for individuals enrolled in these gene transfer trials. Importantly, multivariate analysis suggested that vector-related parameters, including dose, route, transgene, or number of vector administrations at the doses and routes evaluated in these studies, do not appear to be significant risk factors for a major adverse event. With the caveat that these are phase I, uncontrolled trials, we conclude that (1) there is no definitive risk factor that will clearly predict a major adverse outcome resulting from local administration of low and intermediate doses of Ad gene transfer vectors; and (2) major adverse events in these gene transfer trials are associated primarily with the study population and/or trial procedures, not the Ad vectors themselves. This assessment is consistent with the concept that local administration of low and intermediate doses of Ad gene transfer vectors appears to be well tolerated.

Original languageEnglish
Pages (from-to)65-100
Number of pages36
JournalHuman Gene Therapy
Volume13
Issue number1
DOIs
Publication statusPublished - 1 Jan 2002
Externally publishedYes

Fingerprint

Adenoviridae
Genes
Transgenes
Multivariate Analysis
Respiratory Mucosa
Anti-Idiotypic Antibodies
Myocardium
Skeletal Muscle
Skin
Incidence
Population
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. / Crystal, Ronald; Harvey, Ben Gary; Wisnivesky, Juan P.; O’Donoghue, Kelley A.; Chu, Karen W.; Maroni, Jaman; Muscat, Jolene C.; Pippo, Allison L.; Wright, Connie E.; Kaner, Robert J.; Leopold, Philip L.; Kessler, Paul D.; Rasmussen, Henrik S.; Rosengart, Todd K.; Hollmann, Charleen.

In: Human Gene Therapy, Vol. 13, No. 1, 01.01.2002, p. 65-100.

Research output: Contribution to journalArticle

Crystal, R, Harvey, BG, Wisnivesky, JP, O’Donoghue, KA, Chu, KW, Maroni, J, Muscat, JC, Pippo, AL, Wright, CE, Kaner, RJ, Leopold, PL, Kessler, PD, Rasmussen, HS, Rosengart, TK & Hollmann, C 2002, 'Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions', Human Gene Therapy, vol. 13, no. 1, pp. 65-100. https://doi.org/10.1089/10430340152712647
Crystal, Ronald ; Harvey, Ben Gary ; Wisnivesky, Juan P. ; O’Donoghue, Kelley A. ; Chu, Karen W. ; Maroni, Jaman ; Muscat, Jolene C. ; Pippo, Allison L. ; Wright, Connie E. ; Kaner, Robert J. ; Leopold, Philip L. ; Kessler, Paul D. ; Rasmussen, Henrik S. ; Rosengart, Todd K. ; Hollmann, Charleen. / Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. In: Human Gene Therapy. 2002 ; Vol. 13, No. 1. pp. 65-100.
@article{08fc24f23f864592af567a644ed24b1e,
title = "Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions",
abstract = "In this study we analyze the adverse events and abnormal laboratory parameters following local administration of low (<109particle units) and intermediate (109-1011particle units) single and repetitive doses (140 total) of E1E3adenovirus (Ad) gene transfer vectors administered to the respiratory epithelium, solid tumors, skin, myocardium, and skeletal muscle in eight gene transfer trials since April 1993. In the accompanying paper by Harvey et al., (Hum. Gene Ther. 2002; 13:15-63), we conclude that for the total group, no deaths were attributable to the Ad vectors per se, and the incidence of major adverse events likely caused by an Ad vector was 0.7{\%}. The present study analyzes the trials as a group to evaluate risk factors for the adverse events, abnormal values among laboratory parameters, and known deaths. Ten putative risk factors were assessed, including {"}patient-related{"} (age, sex, comorbid index and pretherapy anti-Ad antibodies), {"}vector-related{"} (dose, route, transgene, and number of vector administrations), and {"}trial-related{"} (trial in which the individual was enrolled, and whether surgery was part of the trial). While assessment of each factor individually suggested several possible associations with adverse events, abnormal laboratory parameters, or deaths, multivariate analysis identified only age, comorbid index, and surgery (comorbid index for death; age and surgery for nondeath adverse events) as variables significantly associated with increased risk for a major (severity scale 3-4 of 4) adverse event for individuals enrolled in these gene transfer trials. Importantly, multivariate analysis suggested that vector-related parameters, including dose, route, transgene, or number of vector administrations at the doses and routes evaluated in these studies, do not appear to be significant risk factors for a major adverse event. With the caveat that these are phase I, uncontrolled trials, we conclude that (1) there is no definitive risk factor that will clearly predict a major adverse outcome resulting from local administration of low and intermediate doses of Ad gene transfer vectors; and (2) major adverse events in these gene transfer trials are associated primarily with the study population and/or trial procedures, not the Ad vectors themselves. This assessment is consistent with the concept that local administration of low and intermediate doses of Ad gene transfer vectors appears to be well tolerated.",
author = "Ronald Crystal and Harvey, {Ben Gary} and Wisnivesky, {Juan P.} and O’Donoghue, {Kelley A.} and Chu, {Karen W.} and Jaman Maroni and Muscat, {Jolene C.} and Pippo, {Allison L.} and Wright, {Connie E.} and Kaner, {Robert J.} and Leopold, {Philip L.} and Kessler, {Paul D.} and Rasmussen, {Henrik S.} and Rosengart, {Todd K.} and Charleen Hollmann",
year = "2002",
month = "1",
day = "1",
doi = "10.1089/10430340152712647",
language = "English",
volume = "13",
pages = "65--100",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions

AU - Crystal, Ronald

AU - Harvey, Ben Gary

AU - Wisnivesky, Juan P.

AU - O’Donoghue, Kelley A.

AU - Chu, Karen W.

AU - Maroni, Jaman

AU - Muscat, Jolene C.

AU - Pippo, Allison L.

AU - Wright, Connie E.

AU - Kaner, Robert J.

AU - Leopold, Philip L.

AU - Kessler, Paul D.

AU - Rasmussen, Henrik S.

AU - Rosengart, Todd K.

AU - Hollmann, Charleen

PY - 2002/1/1

Y1 - 2002/1/1

N2 - In this study we analyze the adverse events and abnormal laboratory parameters following local administration of low (<109particle units) and intermediate (109-1011particle units) single and repetitive doses (140 total) of E1E3adenovirus (Ad) gene transfer vectors administered to the respiratory epithelium, solid tumors, skin, myocardium, and skeletal muscle in eight gene transfer trials since April 1993. In the accompanying paper by Harvey et al., (Hum. Gene Ther. 2002; 13:15-63), we conclude that for the total group, no deaths were attributable to the Ad vectors per se, and the incidence of major adverse events likely caused by an Ad vector was 0.7%. The present study analyzes the trials as a group to evaluate risk factors for the adverse events, abnormal values among laboratory parameters, and known deaths. Ten putative risk factors were assessed, including "patient-related" (age, sex, comorbid index and pretherapy anti-Ad antibodies), "vector-related" (dose, route, transgene, and number of vector administrations), and "trial-related" (trial in which the individual was enrolled, and whether surgery was part of the trial). While assessment of each factor individually suggested several possible associations with adverse events, abnormal laboratory parameters, or deaths, multivariate analysis identified only age, comorbid index, and surgery (comorbid index for death; age and surgery for nondeath adverse events) as variables significantly associated with increased risk for a major (severity scale 3-4 of 4) adverse event for individuals enrolled in these gene transfer trials. Importantly, multivariate analysis suggested that vector-related parameters, including dose, route, transgene, or number of vector administrations at the doses and routes evaluated in these studies, do not appear to be significant risk factors for a major adverse event. With the caveat that these are phase I, uncontrolled trials, we conclude that (1) there is no definitive risk factor that will clearly predict a major adverse outcome resulting from local administration of low and intermediate doses of Ad gene transfer vectors; and (2) major adverse events in these gene transfer trials are associated primarily with the study population and/or trial procedures, not the Ad vectors themselves. This assessment is consistent with the concept that local administration of low and intermediate doses of Ad gene transfer vectors appears to be well tolerated.

AB - In this study we analyze the adverse events and abnormal laboratory parameters following local administration of low (<109particle units) and intermediate (109-1011particle units) single and repetitive doses (140 total) of E1E3adenovirus (Ad) gene transfer vectors administered to the respiratory epithelium, solid tumors, skin, myocardium, and skeletal muscle in eight gene transfer trials since April 1993. In the accompanying paper by Harvey et al., (Hum. Gene Ther. 2002; 13:15-63), we conclude that for the total group, no deaths were attributable to the Ad vectors per se, and the incidence of major adverse events likely caused by an Ad vector was 0.7%. The present study analyzes the trials as a group to evaluate risk factors for the adverse events, abnormal values among laboratory parameters, and known deaths. Ten putative risk factors were assessed, including "patient-related" (age, sex, comorbid index and pretherapy anti-Ad antibodies), "vector-related" (dose, route, transgene, and number of vector administrations), and "trial-related" (trial in which the individual was enrolled, and whether surgery was part of the trial). While assessment of each factor individually suggested several possible associations with adverse events, abnormal laboratory parameters, or deaths, multivariate analysis identified only age, comorbid index, and surgery (comorbid index for death; age and surgery for nondeath adverse events) as variables significantly associated with increased risk for a major (severity scale 3-4 of 4) adverse event for individuals enrolled in these gene transfer trials. Importantly, multivariate analysis suggested that vector-related parameters, including dose, route, transgene, or number of vector administrations at the doses and routes evaluated in these studies, do not appear to be significant risk factors for a major adverse event. With the caveat that these are phase I, uncontrolled trials, we conclude that (1) there is no definitive risk factor that will clearly predict a major adverse outcome resulting from local administration of low and intermediate doses of Ad gene transfer vectors; and (2) major adverse events in these gene transfer trials are associated primarily with the study population and/or trial procedures, not the Ad vectors themselves. This assessment is consistent with the concept that local administration of low and intermediate doses of Ad gene transfer vectors appears to be well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0036147182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036147182&partnerID=8YFLogxK

U2 - 10.1089/10430340152712647

DO - 10.1089/10430340152712647

M3 - Article

C2 - 11779413

AN - SCOPUS:0036147182

VL - 13

SP - 65

EP - 100

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -